WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210's favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results